RobertNormanTaubMD

Oncology • New York, NY

Hematologic Oncology, Sarcoma

Physician

Join to view full profile

Dr. Taub is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Taub's full profile

Already have an account?

Office
177 Fort Washington Ave
New York, NY 10032
Phone+1 212-305-4076

Education & Training

Tufts Medical CenterResidency, Internal Medicine, 1963 - 1966
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 1962 - 1963
Tufts Medical CenterInternship, Internal Medicine, 1961 - 1962
Yale School of MedicineClass of 1961
Yale-New Haven Medical CenterFellowship, Medical Oncology

Certifications & Licensure

NY State Medical License 1968 - 2026
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1974

Clinical Trials

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 1998 Sep 01
Unknown status
Phase 2
Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma Start of enrollment: 1997 Jul 01
Unknown status
Phase 2
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Start of enrollment: 1999 Feb 01
Completed
Phase 2
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2000 Oct 01
Unknown status
Phase 2
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Start of enrollment: 2001 May 01
Unknown status
Phase 2
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2001 Oct 01
Unknown status
Phase 2
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Start of enrollment: 2002 Mar 01
Unknown status
Phase 2
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide Start of enrollment: 2007 Oct 01
Unknown status
Phase 1
Sunitinib in Certain Subtypes of Soft Tissue Sarcomas Start of enrollment: 2007 Apr 01
Terminated
Phase 2
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Start of enrollment: 2004 Apr 01
Completed
Phase 2
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Start of enrollment: 2008 Feb 01
Terminated
Phase 2
Alimta Plus Gemcitabine for Advanced Sarcoma Start of enrollment: 2005 Aug 01
Completed
Phase 2
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Start of enrollment: 2009 Sep 01
Unknown status
Phase 2
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Start of enrollment: 2010 Apr 12
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

38 citations
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration
Alain C. Borczuk, Jianming Pei, Robert N. Taub, Brynn Levy, Odelia Nahum
Cancer Biology & Therapy. 2016-02-06
38 citations
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
Alain C. Borczuk, G.C.A. Cappellini, Hoon Kim, Mary Hesdorffer, Robert N. Taub
Oncogene. 2007-01-25
67 citations
Combined heart and lung transplantation for unresectable primary cardiac sarcoma
Susan Talbot, Robert N. Taub, Mary L. Keohan, Niloo M. Edwards, Mark Galantowicz
The Journal of Thoracic and Cardiovascular Surgery. 2002-12-01

Grant Support

Moab-Dnr Conjugates For Therapy--Drug Resistant LeukemiaNational Cancer Institute1989
Moab:Dnr Conjugates For Therapy Of Drug Resistant LeukemNational Cancer Institute1988
Membrane Sialoglycoconjugates And SialyltransferasesNational Cancer Institute1988
Membrane Sialoglycoconjugates And Sialyltransferases InNational Cancer Institute1986–1987
DNR Conjugates For Therapy Of Drug Resistant LeukemiaNational Cancer Institute1986

RobertNormanTaubMD

Dr. Taub is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.